anonymous
Guest
anonymous
Guest
Romark is an interesting place, it has one product in 2 formulations since 2004. It is a private company so company books are not truly open. We believe what they tell us, or not. The patents are up and they have not moved ahead with any "new" product, just investigating a line extension which isn't working well. They have built out an organization with all the right functions but it is more like inviting everyone to a party and not serving any food or drink. People just busy themselves with very little new business to do, but are busy correcting years of mistakes and poor less than perfect management decisions. Sales are asked to sell a product for which there is no approved market so they sell off label and hide it. That's why the base salary is high because the sales are low. But if they are willing to pay a paycheck, then any port in the storm is welcome. I wonder how long the investors are willing to wait... oh, that's right they get dividends paid out from money collected from new unaware investors, so the story plays on. With all the high overhead, the clock is ticking.